Group items tagged

"A vaccine authorized in December for use in India may help solve one of the most vexing problems in global public health: How to supply lower-income countries with a COVID-19 vaccine that is safe, effective and affordable. The vaccine is called CORBEVAX. It uses old but proven vaccine technology and can be manufactured far more easily than most, if not all, of the COVID-19 vaccines in use today."

"Efficacy is a crucial concept in vaccine trials, but it's also a tricky one. If a vaccine has an efficacy of, say, 95 percent, that doesn't mean that 5 percent of people who receive that vaccine will get Covid-19. And just because one vaccine ends up with a higher efficacy estimate than another in trials doesn't necessarily mean it's superior. Here's why."

"Yale University researchers have developed a novel vaccine that in guinea pigs offers protection against infection by the bacterium that causes Lyme disease and may also combat other tick-borne diseases. Instead of triggering an immune response against a particular pathogen, the new vaccine prompts a quick response in the skin to components of tick saliva, limiting the amount of time that ticks have to feed upon and infect the host, the study shows. The vaccine is delivered by the same mRNA technology that has proved so effective against COVID-19."

"Earlier this year, clinical trials of the Moderna and Pfizer-BioNTech vaccines indicated that both immunizations appeared to protect for at least six months. Now, a study in the journal Nature provides some hopeful news that these mRNA vaccines may be protective even longer [1]."

Recommended by Tyler Orion: "Lipid nanoparticles are essential to the Moderna and Pfizer/BioNTech vaccines - and we're staring down a shortage. By Rebecca Heilweil Mar 3, 2021, 11:30am EST"

Recommended by DeAunne Denmark, MD, PhD : "The projects these companies are working on can be organized into three distinct groups: Diagnostics: Quickly and effectively detecting the disease in the first place Treatments: Alleviating symptoms so people who have disease experience milder symptoms, and lowering the overall mortality rate Vaccines: Preventing transmission by making the population immune to COVID-19"

"Breakthrough Infections in Vaccinated People Less Likely to Cause 'Long COVID'"

VLA15 is currently the only active vaccine program in clinical development against Lyme disease. VLA15 is a multivalent recombinant protein vaccine that targets six serotypes of Borrelia representing the most common pathogenic strains found in the United States and Europe. Valneva has completed recruitment and reported initial results for two Phase 2 clinical trials [5,6] of VLA15 in over 800 healthy adults and in which Valneva observed high levels of antibodies against all six serotypes. Valneva announced a collaboration with Pfizer for late phase development and, if approved, commercialization of VLA15 [7]. As part of its collaboration with Pfizer, Valneva accelerated the pediatric development of VLA15 with an additional Phase 2 clinical trial initiated in March 2021. In July 2021, Pfizer and Valneva announced recruitment completion for VLA15-221 with a total of 625 participants, 5 to 65 years of age [8]. The VLA15 program was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) in July 2017 [9].

"David A. Broniatowski et al. "Weaponized Health Communication: Twitter Bots and Russian Trolls Amplify the Vaccine Debate", American Journal of Public Health 108, no. 10 (October 1, 2018): pp. 1378-1384. https://doi.org/10.2105/AJPH.2018.304567"

Recommended by DeAunne "For the first time ever, scientists at the Human Vaccines Project are combining systems biology with artificial intelligence to understand one of the greatest remaining frontiers of human health, the human immune system. Modeled after the transformative Human Genome Project, the Human Vaccines Project is leveraging cutting-edge technologies to decode the human immune system. Our scientists are working to unlock new preventions, diagnostics, and treatments for some of the world's most devastating diseases."

This is a good how-to guide. Share it!

"An FDA advisory panel recommended emergency use authorization (EUA) of a booster dose of Moderna's COVID-19 vaccine for adults ages 65 and older, as well as for younger adults with high-risk medical conditions or at high risk of occupational or institutional exposure."

Folks, this recent piece on Medium will help us all get a sense of the big vision driving Dr. Cahana's passions. "UHI Universal Health Income, on the other hand is designed to encourage healthy behaviors (such as vaccinations, prenatal care, periodic or annual check ups) and discourage risky behaviors (like smoking, addiction, not adhering to treatment or in the case of COVID- avoiding social distancing)."

Recommended by Janice O'Connor: "As the world awaits vaccines to bring the COVID-19 pandemic under control, UC San Francisco scientists have devised a novel approach to halting the spread of SARS-CoV-2, the virus that causes the disease."

The COVID-19 pandemic makes it necessary for leading experts from across disciplines and geographies to come together to jointly address the challenges we are facing when coping with the disruptive nature of the coronavirus SARS-CoV-2 pandemic is having on our healthcare system and our society as a whole. The tasks upon us are enormous and include besides decoding the virus and scaling diagnostics, tackling COVID-19 within existing healthcare systems, building health data platforms that support COVID-19 focused health care, accommodating clinical trials in the era of COVID-19, and developing functional vaccines and therapeutics. The next PMWC 2021 on January 25-27 would be a virtual conference and will touch upon these critical developments and ongoing activities while also including the regulatory and investment sides that influence clinical advancements.

"Eight ways in which scientists hope to provide immunity to SARS-CoV-2 ."